Biotech Values

[DewDiligence]

(ENTA)—Paxlovid trial misses primary endpoint in post-exposure prophylaxis:

https://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-top-line-results-phase-23-epic-pep-study

Pfizer Inc. today shared top-line results from the Phase 2/3 EPIC-PEP study evaluating PAXLOVID…for post-exposure prophylactic use. In this trial, compared to placebo, Pfizer observed risk reductions of 32% and 37% in adults who received PAXLOVID for five and ten days, respectively, to prevent infection. These results, however, were not statistically significant and, as such, the primary endpoint of reducing the risk of confirmed and symptomatic COVID-19 infection in adults who had been exposed to the virus through a household contact was not met.

The opening for ENTA's EDP-235 just got wider.